Tag: Randall Bateman

Highly accurate blood test diagnoses Alzheimer’s disease, measures extent of dementia

A newly developed blood test for Alzheimer’s disease not only aids in the diagnosis of the neurodegenerative condition but also indicates how far it has progressed, according to a study by researchers at Washington University School of Medicine in St. Louis and Lund University in Sweden. Several blood tests for Alzheimer’s disease are already clinically […]

Patient defies genetic fate to avoid Alzheimer’s

Remarkably, Doug Whitney, 75, has escaped genetic destiny. Like many members of his family, Whitney inherited a rare genetic mutation that all but guarantees he would develop early-onset Alzheimer’s disease. But Whitney, whose relatives first showed symptoms of cognitive decline in their early 50s, remains mentally sharp with no signs of the devastating disease, and […]

‘Here and Next’ Seed Grants awarded

Washington University in St. Louis’ Research Development Office recently awarded its latest batch of “Here and Next” Seed Grants. The winning research teams are interdisciplinary and focus on five key elements of the university’s strategic plan: public health, global health, environmental research, digital transformation and research that impacts the St. Louis community. There are three […]

Newly opened Jeffrey T. Fort Neuroscience Research Building dedicated

Dozens of noted scientists, philanthropists, and university, state and local leaders gathered Jan. 18 to celebrate the dedication of one of the world’s largest neuroscience research buildings, a gleaming state-of-the-art facility on the Washington University Medical Campus. They toured its sophisticated, newly christened labs; listened intently as Washington University scientists described the lifesaving work they […]

Tau-based biomarker tracks Alzheimer’s progression

Two pathologies drive the progression of Alzheimer’s disease. Early on, amyloid beta plaques lead the way, but around the time cognitive symptoms arise, tau tangles take over as the driving force and cognition steadily declines. Tracking the course of the disease in individual patients has been challenging because there’s been no easy way to measure […]